SCHEMBL3926091

SCHEMBL3926091

COC(=O)C1(NC(=O)c2ccc3ccccc3c2OCc2ccc(C(F)(F)F)cc2)CC=CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 4/20 0.59
DRD4 P21917 1/20 0.39
LMNA P02545 2/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 2/20 0.39
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ADAM17 P78536 1/20 0.39
TRPV1 Q8NER1 1/20 0.38
SLC6A5 Q9Y345 3/20 0.37
P2RX1 P51575 1/20 0.37
P2RX3 P56373 1/20 0.37
P2RX4 Q99571 1/20 0.37
P2RX7 Q99572 1/20 0.37
RAB9A P51151 1/20 0.36
MAOB P27338 2/20 0.35
SENP5 Q96HI0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3925954 0.91 CXCR2 (0.61) CXCR2DRD4ALDH1A1GAAMAPT
SCHEMBL3922449 0.89 CXCR2 (0.56) CXCR2DRD4LMNAALDH1A1GAA
SCHEMBL485264 0.85 CXCR2 (0.62) CXCR2DRD4ALDH1A1GAAMAPT
SCHEMBL485673 0.83 CXCR2 (0.62) CXCR2DRD4ALDH1A1GAAMAPT
SCHEMBL485419 0.83 CXCR2 (0.61) CXCR2DRD4TRPV1SLC6A5P2RX1
SCHEMBL3925807 0.81 CXCR2 (0.58) CXCR2DRD4ALDH1A1GAAMAPT
SCHEMBL3934321 0.80 CXCR2 (0.66) CXCR2DRD4LMNAALDH1A1GAA
SCHEMBL3926067 0.80 CXCR2 (0.56) CXCR2DRD4ALDH1A1GAAMAPT
SCHEMBL27713046 0.79 CXCR2 (0.57) CXCR2DRD4ALDH1A1GAAMAPT
SCHEMBL25548913 0.77 CXCR2 (0.60) CXCR2DRD4LMNAALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2040690-B1 INHIBITORS OF CXCR2 SANOFI SA (FR) 2014-08-06 EP disclosed
US-8552033-B2 Inhibitors of CXCR2 SANOFI (FR) 2013-10-08 US disclosed
US-20090215827-A1 INHIBITORS OF CXCR2 SANOFI-AVENTIS (FR) 2009-08-27 US disclosed
EP-2040690-A1 INHIBITORS OF CXCR2 Sanofi-Aventis (FR) 2009-04-01 EP disclosed
WO-2008000407-A1 INHIBITORS OF CXCR2 SANOFI-AVENTIS (FR) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215827-A1 INHIBITORS OF CXCR2 CXCR2, CXCR1, CXCR4 CXCR2 1/4885DRD4 2934/4885LMNA 4490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.